Work Together.
Cure Cancer.
Recent Developments
August 2024
CureMeta has completed the humanization of our lead therapeutic cancer antibody, CM-09.
Bstrazumab, CM-14, is a humanized IgG1 antibody with the same binding and biophysical characteristics as the mouse and the mouse/human chimeric versions of the antibody. Bstrazumab binds with
high affinity and specificity to the cancer stem cell marker TRA-1-60, an embryonic antigen found on cancer cells within solid tumors with stem cell properties.
Recent publication with CureMeta therapeutic antibodies and antibody-drug-conjugates:
Pathological and Biological Significance of the Specific Glycan, TRA-1-60, on Aggressive Gastric Adenocarcinoma.
This report describes the use of CureMeta’s TRA-1-60 specific antibody-drug-conjugate, CM-09, in a metastatic gastric cancer mouse model and shows a significant therapeutic impact in advanced-stage gastric cancers.
Link here for publication: https://pubmed.ncbi.nlm.nih.gov/38718982/
Upcoming Events
June 2024 - December 2024
Humanize Bstrongximab therapeutic antibody (completed)
Produce humanized CM-09 Antibody-Drug-Conjugate
Efficacy, Animal Toxicity and PK/PD/Characterization studies
January 2025 - June 2026
Begin IND-enabling studies
File IND with FDA
July 2026
Begin Phase 1 clinical study with pancreatic and gastric cancer patients
Advance CureMeta’s antibody pipeline
About
We are a Boston-based biotech company developing antibodies to novel cancer targets and Antibody-Drug-Conjugates (ADC) therapeutics to treat and cure patients with metastatic cancers.
Our drug development strategy is centered around embryonic cancer targets that are not present in normal healthy tissues and present in aggressive and metastatic cancers.
The Science
The Cancer Problem: There are no good drugs for
treating metastatic cancer.
CureMeta’s Solution: New drugs to target and kill
the cancer stem cells responsible for tumor origin, progression, resistance, and metastasis
● Metastatic cancer is the cause of death in over 90% of patients with solid tumors.
● In just the US, over 63,000 patients with pancreatic or gastric cancer will die in 2024.
● CureMeta’s drug development strategy is based on the premise that cancer is caused by malignant undifferentiated cancer cells with stem cell properties including embryonic stem cell properties.
● CureMeta is developing new antibody-based drugs specific for embryonic cancer targets that are not found in normal tissue but present only on cancer stem cells in the tumor.
CureMeta’s Lead Therapeutic:
CM-09/CM-14
We have developed a proprietary antibody-discovery platform to generate monoclonal antibodies, to novel and untested cancer targets. We used Bstrongximab to generate a powerful antibody-drug conjugate, CM-09, which targets and kills gastric and pancreatic cancer.
CureMeta’s Next Step:
Human Clinical Trials
We are transitioning from a preclinical to a clinical biotech and preparations are underway to take CM-14 into a human clinical cancer trial. During this next step, we will complete a human clinical phase 1 trial to generate safety and efficacy data in patients with these metastatic cancers. We anticipate minimal toxicity in the trial because the cancer target TRA-1-60 is not found in normal healthy tissues. Currently, there are no effective cancer treatments that offer any meaningful benefits or quality of life to patients suffering from these metastatic cancers. CM-14 has the potential to be a first-in-class humanized ADC to treat patients with pancreatic and gastric cancers.
Learn More.